Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cumberland PharmaceuticalsCPIX -4.27%36 EV-to-OCF is 150.86 as of Aug. 11, 2026, which is 1849% above its 10-year median of 7.74. GuruFocus rates CPIX with a GF Score™ of 36/100 and a GF Value™ of $2.40 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Cumberland Pharmaceuticals ranks worse than 95.43% on this metric.
The historical rank and industry rank for Cumberland Pharmaceuticals's EV-to-OCF or its related term are showing as below:
CPIX'
s EV-to-OCF Range Over the Past 10 Years
Min: -149.2 Med: 7.74 Max: 3167.45
Current: 150.86
During the past 13 years, the highest EV-to-OCF of Cumberland Pharmaceuticals was 3167.45. The lowest was -149.20. And the median was 7.74.
CPIX's EV-to-OCF is ranked worse than 95.43% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.055
vs CPIX: 150.86
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cumberland Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Cumberland Pharmaceuticals's share price for today is $7.4767.
Cumberland Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.730.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cumberland Pharmaceuticals EV-to-OCF Related Terms
Cumberland Pharmaceuticals EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cumberland Pharmaceuticals EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cumberland Pharmaceuticals's EV-to-OCF falls into.
Cumberland Pharmaceuticals's current Enterprise Value is $112.54 Mil.
Cumberland Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cumberland Pharmaceuticals (CPIX) has a EV-to-OCF of 150.86 as of Aug. 11, 2026. This is 1849% above median its historical median of 7.74. According to the industry distribution chart, Cumberland Pharmaceuticals ranks #960 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 95.4%.
Is Cumberland Pharmaceuticals' EV-to-OCF too high?
Cumberland Pharmaceuticals' current EV-to-OCF of 150.86 is 1849% above median its 10-year median of 7.74. The Drug Manufacturers industry median EV-to-OCF is 11.06. Cumberland Pharmaceuticals' value of 150.86 is 1264.6% above this industry median. Based on the distribution chart, Cumberland Pharmaceuticals ranks #960 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cumberland Pharmaceuticals has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cumberland Pharmaceuticals' EV-to-OCF compare to BGM and ZYBT?
According to the Drug Manufacturers industry distribution chart, Cumberland Pharmaceuticals ranks #960 out of 1006 companies for EV-to-OCF. This places Cumberland Pharmaceuticals in the lower half of its industry. The industry median EV-to-OCF is 11.06. Cumberland Pharmaceuticals' value of 150.86 is 1264.6% above this benchmark. While the company's 10-year median is 7.74 vs. the industry median of 11.06, Cumberland Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.06, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cumberland Pharmaceuticals's current EV-to-OCF of 150.86 is 1264.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cumberland Pharmaceuticals's current EV-to-OCF is 150.86, which is 1849% above median its own 10-year median of 7.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cumberland Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals (CPIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.40, compared to a current price of $7.48 — trading 211.5% above its estimated fair value. The current EV-to-OCF is 150.86, which is 1849% above median its 10-year median of 7.74 and 1264.6% above the Drug Manufacturers industry median of 11.06. Cumberland Pharmaceuticals' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cumberland Pharmaceuticals (CPIX), the current EV-to-OCF is 150.86 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cumberland Pharmaceuticals (CPIX) Overvalued in 2026?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals stock appears to be overvalued.
The current stock price of $7.48 is trading 211.5% above its estimated GF Value™ of $2.40.
GuruFocus considers Cumberland Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CPIX:
EV-to-OCF: 150.86 (1849% above median its 10-year median of 7.74)
GF Value™: $2.40 vs. price of $7.48 (211.5% above fair value)
Industry Position: 1264.6% above the Drug Manufacturers median (#960 of 1006)
No single metric tells the full story. See the CPIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
36GF Score
Get the complete analysis for CPIX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPIX has been successfully added to your 
